PMID- 35961441
OWN - NLM
STAT- MEDLINE
DCOM- 20221129
LR  - 20221206
IS  - 1878-5492 (Electronic)
IS  - 0966-3274 (Linking)
VI  - 75
DP  - 2022 Dec
TI  - The analysis of immunosuppressant therapy adherence, depression, anxiety, and 
      stress in kidney transplant recipients in the post-transplantation period.
PG  - 101686
LID - S0966-3274(22)00160-5 [pii]
LID - 10.1016/j.trim.2022.101686 [doi]
AB  - AIM: Our study aimed to analyze the immunosuppressant therapy adherence, anxiety, 
      stress, and depression in kidney transplant recipients in the 
      post-transplantation period. METHOD: This study was conducted as descriptive and 
      cross-sectional research with the participation of 260 recipients who underwent 
      kidney transplantation and were already discharged from the hospital (n = 260). 
      In the data collection process, we used the Personal Information Form, the 
      Immunosuppressant Therapy Adherence Scale (ITAS), and the Depression Anxiety 
      Stress Scale (DASS)-21. The One-Way Analysis of Variance (ANOVA), Chi-Squared 
      test, post hoc and Pearson Correlation analysis methods were used in data 
      analysis. FINDINGS: In our study all participant kidney transplant recipients, 
      45.4% were age 46-64 years and 81.5% were men. As the recipients' age levels 
      increased, their immunosuppressant therapy adherence levels decreased (p < 0.05). 
      Similarly, kidney recipients with at least 3 adverse events (infection, 
      gastrointestinal problems, edema, blood disorders etc.) had a higher DASS-21 
      score and a lower ITAS score than those with low side effects. ITAS had a strong 
      negative relationship with DASS-21 (p < 0.05). Recipients' depression, stress, 
      and anxiety scores were, in general, above the medium level. CONCLUSION: 
      Adherence to the immunosuppressive drug regimen after kidney transplantation and 
      depression, anxiety and stress are in a bidirectional relationship. At the same 
      time, the side effects of immunosuppressive drugs can trigger the development of 
      depression, anxiety and stress. After kidney transplant, recipients are at risk 
      for the development of depression, anxiety, and stress. We recommend early 
      detection of this condition and taking preventive and symptom-reducing 
      interventions.
CI  - Copyright (c) 2022 Elsevier B.V. All rights reserved.
FAU - Uyar, Betul
AU  - Uyar B
AD  - Department of Psychiatry, Faculty of Medicine, Dicle University, Diyarbakir, 
      Turkey. Electronic address: betul.uyar@dicle.edu.tr.
LA  - eng
PT  - Journal Article
DEP - 20220809
PL  - Netherlands
TA  - Transpl Immunol
JT  - Transplant immunology
JID - 9309923
RN  - 0 (Immunosuppressive Agents)
SB  - IM
MH  - Male
MH  - Humans
MH  - Middle Aged
MH  - Female
MH  - *Immunosuppressive Agents/therapeutic use
MH  - *Kidney Transplantation
MH  - Cross-Sectional Studies
MH  - Depression/epidemiology
MH  - Medication Adherence
MH  - Transplant Recipients
MH  - Anxiety/drug therapy/epidemiology
OTO - NOTNLM
OT  - Anxiety
OT  - Depression
OT  - Immunosuppressant therapy
OT  - Kidney transplantation
OT  - Stress
EDAT- 2022/08/13 06:00
MHDA- 2022/11/30 06:00
CRDT- 2022/08/12 19:24
PHST- 2022/06/20 00:00 [received]
PHST- 2022/08/06 00:00 [revised]
PHST- 2022/08/07 00:00 [accepted]
PHST- 2022/08/13 06:00 [pubmed]
PHST- 2022/11/30 06:00 [medline]
PHST- 2022/08/12 19:24 [entrez]
AID - S0966-3274(22)00160-5 [pii]
AID - 10.1016/j.trim.2022.101686 [doi]
PST - ppublish
SO  - Transpl Immunol. 2022 Dec;75:101686. doi: 10.1016/j.trim.2022.101686. Epub 2022 
      Aug 9.